Breaking News
Investing Pro 0

Exelixis (EXEL) In-Licenses Aurigene's Compound, Files IND

By Zacks Investment ResearchStock MarketsDec 08, 2020 01:32AM ET
www.investing.com/analysis/exelixis-exel-inlicenses-aurigenes-compound-files-ind-200547233
Exelixis (EXEL) In-Licenses Aurigene's Compound, Files IND
By Zacks Investment Research   |  Dec 08, 2020 01:32AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
 
MSFT
+2.32%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
BMY
-0.15%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
HALO
-1.39%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
EXEL
-0.64%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

Exelixis (NASDAQ:EXEL), Inc. EXEL and partner Aurigene announced that the former has exercised its exclusive option for the latter’s novel CDK7 inhibitor under their 2019 agreement.

As a result, the company now assumed responsibility for the future clinical development, commercialization and global manufacturing of the compound, now known as XL102 (formerly AUR102).

XL102 is a potent, selective and orally bioavailable covalent inhibitor of cyclin-dependent kinase 7 (CDK7), which is an important regulator of the cellular transcriptional and cell cycle machinery.

Exelixis also submitted an Investigational New Drug Application (IND) to the FDA for evaluating XL102 alone or in a combination therapy for the treatment of inoperable locally advanced or metastatic solid tumors. The phase I study is expected to begin in the first quarter of 2021.

We note that Aurigene is a development-stage biotech company and a wholly-owned subsidiary of Dr. Reddy’s Laboratories Ltd. RDY.

The addition of the candidate will solidify Exelixis’ pipeline.

Per the terms of the agreement, Exelixis made an upfront payment of $10 million for exclusive options to license three pre-existing programs including XL102 from Aurigene.

Additionally, Exelixis and Aurigene initiated three drug discovery programs, led by the latter on mutually agreed-upon targets, in exchange for an additional upfront option payment of $2.5 million per program.

The company is also contributing to Aurigene’s research funding for facilitating the discovery and preclinical development work on all six programs. Exelixis will have the opportunity to exercise an exclusive option for each program until the time of IND filing acceptance as the programs mature. Upon exercising an option, Exelixis will make an option exercise payment to the latter and assume responsibility for that program’s future clinical development and commercialization including global manufacturing. Notably, the company will make an option exercise payment of $12 million to exercise its option for XL102.

Aurigene will also be eligible for clinical development, regulatory and sales milestones as well as royalties on sales after Exelixis in-licenses a program. Under the terms of their deal, the partner entity retains the limited development and commercial rights for India and Russia.

Last week, Exelixis exercised its exclusive option for Iconic’s lead oncology antibody-drug conjugate (ADC) program under the companies’ May 2019 agreement.

Shares of Exelixis have increased 7.6% in the year so far compared with the industry’s growth of 5.9%.

The pipeline progress has been encouraging in the year so far. Cabometyx tablets are approved for advanced renal cell carcinoma (RCC) and the previously-treated hepatocellular carcinoma (HCC).

In August 2020, Exelixis announced the submission of a supplemental new drug application (sNDA) to the FDA for cabozantinib in combination with Bristol-MyersBMY Opdivo for patients with advanced RCC. In October 2020, both companies announced that the FDA accepted Exelixis’ sNDA and Bristol-Myers’ supplemental biologics license application (sBLA), granted a Priority Review to both applications and assigned a target action date of Feb 20, 2021.

Exelixis currently carries a Zacks Rank #5 (Strong Sell).

A better-ranked player in the biotech space is Halozyme (NASDAQ:HALO) Therapeutics, Inc. HALO, which carries a Zacks Rank #2 (Buy), presently. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Halozyme’s current-year earnings estimates have been revised 21 cents upward in the past 60 days.

Biggest Tech Breakthrough in a Generation

Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.

A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft (NASDAQ:MSFT) in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.

See 8 breakthrough stocks now>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Dr. Reddys Laboratories Ltd (RDY): Free Stock Analysis Report

Exelixis, Inc. (EXEL): Free Stock Analysis Report

Bristol Myers Squibb Company (NYSE:BMY): Free Stock Analysis Report

Halozyme Therapeutics, Inc. (HALO): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research
Exelixis (EXEL) In-Licenses Aurigene's Compound, Files IND
 

Related Articles

Exelixis (EXEL) In-Licenses Aurigene's Compound, Files IND

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email